Target intelligence / Profile preview

Alpha-cyclodextrin (α-CD)

Target
α-CD
Molecular classification
Cyclic oligosaccharide, Cyclodextrin, Carbohydrate, Other
01

Overview

Alpha-cyclodextrin is a cyclic oligosaccharide composed of six glucose units linked by alpha-1,4-glycosidic bonds, forming a torus-shaped structure with a hydrophobic internal cavity and a hydrophilic exterior. It is naturally produced from starch via enzymatic conversion by cyclodextrin glycosyltransferase and is widely utilized in the pharmaceutical, food, and cosmetic industries. In medicine, it primarily serves as a functional excipient to improve the aqueous solubility, stability, and bioavailability of hydrophobic drugs through the formation of non-covalent host-guest inclusion complexes. Beyond its role as a carrier, alpha-cyclodextrin acts as a soluble dietary fiber that can physically sequester dietary lipids and cholesterol in the gastrointestinal tract, thereby reducing their absorption and lowering serum lipid levels. It also demonstrates the ability to modulate glycemic response by interfering with carbohydrate digestion, potentially through the competitive inhibition of enzymes such as alpha-amylase. While generally recognized as safe (GRAS) for oral consumption, its systemic use is constrained by potential nephrotoxicity and hemolytic activity at high concentrations.

Other names
α-CyclodextrinAlfadexCyclomaltohexaoseSchardinger alpha-dextrinCyclohexaamylose
02

Mechanism of action

Alpha-cyclodextrin acts primarily through the formation of non-covalent host-guest inclusion complexes, where its hydrophobic internal cavity encapsulates lipophilic molecules to enhance their solubility and stability. In the gastrointestinal tract, it functions as a sequestering agent for dietary fats and cholesterol and may inhibit digestive enzymes such as alpha-amylase to modulate carbohydrate absorption.

03

Biological functions

Inclusion complex formationLipid sequestrationCarbohydrate metabolism modulationPrebiotic activityOther
04

Disease associations

HyperlipidemiaObesityType 2 DiabetesCardiovascular diseaseOther
05

Safety considerations

Nephrotoxicity (renal toxicity) upon parenteral administrationHemolysis of erythrocytes at high systemic concentrationsGastrointestinal distress including flatulence and diarrhea at high oral doses
06

Interacting drugs

Alprostadil

8 more in the full profile.

07

Biomarkers

Low-density lipoprotein cholesterolTriglyceridesPostprandial blood glucoseGlycated hemoglobin (HbA1c)

Beyond the preview

Go deeper on Alpha-cyclodextrin (α-CD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-cyclodextrin (α-CD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call